Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Impact · against what's priced in

The settlement creates a significant immediate cash catalyst for ABUS and ROIV, with ABUS explicitly signaling a return of capital to shareholders. For MRNA, the $950M upfront cost and potential $1.3B liability represent a direct hit to the balance sheet, while the resolution of litigation provides operational certainty.

ABUS+0.70

No priced-in read yet